



DEC 2 0 2002

Approved for use through (13) 2007 p. U.S. Petent end Trademark Office: U.S. DE AKT MEDICAL U.S. DE AKT ME

REQUEST FOR

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or piant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

ilection of information unless it displays a valid OMB control nurger 250				
Application Number	09/095,639			
Filing Date	June 11, 1998			
First Named Inventor	Paolo Pozzilli			
Group Art Unit	1632			
Examiner Name	Ton, T.			
Attomey Docket Number	oer 515-4111			

wish to consider filing a the patent term adjustr	§ 1.114 is effective on May 29, 2000. if the ebove-identified a continued prosecution application (CPA) under 37 C.F.R. § 1 nent provisions of the AIPA. See Changes to Application Example, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) ce.	.53 (d) (PTOISBI2 ninetion end Provi	9) Insteed of a RCE to be eiig Isional Application Practice, Fl	nibie for nal Rule, 65	
1. Submission requ	ired under 37 C.F.R. § 1.114				
a. Previously : i. Consider (Any unent	submitted or the amendment(s)/reply under 37 C.F.R. (ered amendment(s) referred to above will be entered).			1	
ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on					
iii. ∐ Other					
b. 🔀 Enclosed i. 🔯 Amendi	ment/Reply ∞				
	t(s)/Declaration(s)				
iii. Information Disclosure Statement (IDS)					
iv.					
2. Miscellaneous					
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) b. Other months = 27.0.5 D 0.4.47(A) a spring by 37.0.5 D 0.4.47(A) as spring by 37.0.5 D 0.					
3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed. a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to					
Deposit Account No. 08-1540					
i. X RCE fee required under 37 C.F.R. § 1.17(e)					
iii. 😠 Other	on of time fee (37 C.F.R. §§ 1.136 and 1.17) A check for \$460.00/ Ext. fee				
	e amount of \$enclose	sed			
c. Payment b	y credit card (Form PTO-2038 enclosed)				
	SIGNATURE OF APPLICANT, ATTOR	NEY, OR AGE	NT REQUIRED		
Name (Print IType)	James V. Costigan	Registra	tion No. (Attorney/Agent)	25,669	
Signature		Date	December 13, 2002	2	
	CERTIFICATE OF MAILING OF	RTRANSMISS	SION		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:					
Name (Print/Type)	James V. Costigan				
Signature	10(14)	Date	December 13, 20		
	s form Is estimated to take 0.2 notice to complete. Time will include to complete this form should be sent to the Chief Information of the Chief I				

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

12/18/2002 SFELEKE1 00000098 09095639

Box RCE, Washington, DC 20231.

01 FC:2801

370.00 OP

RECEIVED

Docket No.: <u>515-4111</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE STATES 1600/2900

PATENT OPERATIONS

16-63

re Application of:

POZZILLI, PAOLO

Group Art Unit: 1632 Examiner: Ton, T.

Serial No.: 09/095,639

Bitamilion.

Filed: June 11, 1998

For: PRODUCT DERIVED FROM MILK SUBSTANTIALLY FREE OF BETA CASEIN

FROM NON-HUMAN MAMMALS AND RELATIVE USE

New York, NY 10036 December 13, 2002

Commissioner for Patents Washington, DC 20231

AMENDMENT

Sir:

El

This Amendment is being filed in response to the Office Action that was mailed June 19, 2002.

IN THE CLAIMS:

Kindly amend claims 28, 33, 35 and 36 as follows:

28. (amended) A dietary or pharmaceutical product, said product comprising at least one modified bovine beta-casein or fragments thereof selected from the group consisting of recombinant or synthetic caseins which do not contain the sequences: Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).

33. (amended) A method for the inhibition of the inductive effect of beta casein and its fragments on insulin-dependent diabetes comprising the step of administering to newborns and infants an immunogenic infant formula free of caseins which exhibits molecular mimicry with protein GLUT2.